Autogenous Vaccines in the Poultry Industry: A Field Perspective

Abstract

Emergent economically important diseases affecting the poultry industry in the face of commercial vaccination programs in place might require custom-made vaccines to be controlled in the field. These custom-made vaccines (“autogenous”), albeit requiring less regulatory burden than fully licensed commercial vaccines, are restricted in their scope and field isolates and can only be used in particular areas/operations. This chapter summarizes field and research experience of the author with some viral and bacterial autogenous vaccine programs (e.g., Avian Reovirus, Fowl Adenovirus, Infectious Bursal Disease Virus, Salmonella enterica spp., Escherichia coli, Clostridium spp.), as well as commentaries on regulations, and adjuvant technologies used in the poultry industry.

Protection of laying chickens against the Canadian DMV/1639 infectious bronchitis virus infection through priming with heterologous live vaccine and boosting with heterologous or homologous inactivated vaccine

“…However, if the infectious agent was found to be antigenically distinct from the conventional strains found in licensed vaccines, an autogenous vaccine option could be considered ( Smith, 2004 ). Unlike standard commercial vaccines that demand extensive testing and rigorous regulatory procedures, autogenous vaccines require more basic testing and a shorter legal process ( Palomino-Tapia, 2023 ). Generally, autogenous vaccines are inactivated and include the isolates recovered from affected flocks.…”